Anika Therapeutics (ANIK) stock vaulted 49% to an all-time high in morning trading on the stock market today, a day after the biotech won FDA approval for its arthritis treatment. After the close Tuesday, Anika said the FDA had approved Monovisc for osteoarthritis of the knee. DePuy Synthes Mitek Sports Medicine, a division of Johnson & Johnson (JNJ), will market Monovisc and pay Anika a $5 million milestone payment, followed by royalties and
The FDA approved Pharmacyclics’ (PCYC) Imbruvica for chronic lymphocytic leukemia early Wednesday afternoon, abruptly sending the stock up nearly 7% on the stock market today. Pharmacyclis and its partner, Johnson & Johnson (JNJ) unit Janssen Biotech, said the agency had approved the product to treat the deadly blood cancer in patients who’d received at least one prior therapy. It’s the second indication for Imbruvica, which was launched back in
Johnson & Johnson (JNJ) said Thursday that it received a binding offer of $4.15 billion from private-equity firm the Carlyle Group for its Ortho-Clinical Diagnostics business. J&J has until March 31 to decide whether to accept the offer. “This transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson,” J&J CEO Alex Gorsky said in a statement. The diversified medical